Panacea Biotec wins Rs 170 crore Pentavalent vaccine orders from UN agencies

Published On 2019-12-20 07:30 GMT   |   Update On 2019-12-20 07:30 GMT

"Panacea Biotec... has received awards worth USD 24.32 million from U N agencies (Unicef and PAHO) for supply of its Easyfive-TT, a fully liquid WHO prequalified wP-based Pentavalent vaccine (DTwPHepB-Hib)," the company said in a filing to BSE.


New Delhi: Panacea Biotec on Thursday said it has bagged orders worth USD 24.32 million (over Rs 170 crore) from UN agencies, including Unicef, for the supply of Pentavalent vaccine. The vaccine protects children against five deadly diseases, including diphtheria, tetanus and hepatitis B.


"Panacea Biotec... has received awards worth USD 24.32 million from U N agencies (Unicef and PAHO) for supply of its Easyfive-TT, a fully liquid WHO prequalified wP-based Pentavalent vaccine (DTwPHepB-Hib)," the company said in a filing to BSE.


The award of order from Unicef is for the calendar year 2020 and from PAHO is for three calendar years--2020 to 2022.


Read Also: Panacea Biotec appoints Rajeeva Kumar Mangalum as Chief Operating Officer for pharmaceutical operations


Pediatric vaccination plays an important role to achieve Sustainable Development Goals set by the United Nations, in particular, the target to reduce the under-five mortality rate to less than 25 per 1,000 live births.


"Pentavalent vaccine protects children against five deadly diseases; Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b - becoming the foundation of pediatric immunization programs across the world," the company said.


Read Also: Panacea Biotec gets USFDA nod for chemotherapy drug Azacitidine

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News